<DOC>
	<DOCNO>NCT02697552</DOCNO>
	<brief_summary>Phase 1 , open-label , non-randomized , dose-escalation study evaluate safety , tolerability , pharmacokinetics ( PK ) , preliminary efficacy HBI-8000 administer orally .</brief_summary>
	<brief_title>Safety Study HBI-8000 Japanese Patients With Non Hodgkin 's Lymphoma</brief_title>
	<detailed_description>Phase 1 , open-label , non-randomized , dose-escalation study evaluate safety , tolerability , pharmacokinetics ( PK ) , preliminary efficacy HBI-8000 administer orally . Patients must hospitalize per guidance treating investigator throughout Cycle 1 . Patients receive HBI 8000 twice weekly ( BIW ) ( breakfast ) , 28 day treatment cycle . Patients enrol cohort 3 patient . The first cohort 3 patient receive 30 mg BIW . Decisions regard cohort escalation base upon clinical experience Cycle 1 ( first 28 day ) . For give cohort , 1 patient enrol cohort experience dose limit toxicity ( DLT ) within 28 day first dose , cohort expand 6 patient .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<criteria>1 . Histologically cytologically diagnose non Hodgkin 's lymphoma patient standard therapy available 2 . Male female , age 20 year time signing inform consent 3 . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 2 life expectancy , per investigator , 3 month time sign informed consent 4 . Patients least 1 measurable lesion confirm lesion assessment start study drug administration 5 . Patients must recover Grade 1 le ( Common Terminology Criteria Adverse Events [ CTCAE ] , Version 4.03 ) toxicity associate previous chemotherapy , antibody , radiotherapy . ( Exception : patient may enter continue alopecia regardless CTCAE grade . ) The following interval end another treatment start HBI8000 must elapse : Chemotherapy : 4 week Nitrosourea : 6 week Radiotherapy : 4 week Major surgery : 4 week Immunomodulatory drug : 4 week Any antibody agent : 12 week ( 84 day ) Autologous stem cell transplantation ( ASCT ) : 12 week ( 84 day ) 6 . Patients must agree consume grapefruit , grapefruit juice , Seville oranges , St.John 's wort , product contain Seville orange , grapefruit , St. John 's wort participation study 7 . Patients sign informed consent form capable give informed consent accordance policy Institutional Review Board ( IRB ) 8 . Patients must willing hospitalize per guidance treating investigator throughout Cycle 1 1 . Patients current , previous , clinically suspect invasion central nervous system ( CNS ) 2 . Organ transplant recipient 3 . Allogeneic stem cell transplant recipients 4 . Previous extensive radiotherapy involve ≥30 % hematopoietic bone marrow , exclude patient total body irradiation part condition regimen ASCT 5 . Patients electrocardiogram ( ECG ) find screen QT interval correct heart rate use Fridericia 's method ( QTcF ) prolongation &gt; 450 ms male patient &gt; 470 ms female patient , ventricular tachycardia , ventricular fibrillation , second thirddegree heart block , unstable angina , coronary angioplasty stenting , myocardial infarction , chronic congestive heart failure ( New York Heart Association Class III IV ) within 6 month start study drug , cardiomyopathy , long QT syndrome 6 . Any condition include presence laboratory abnormality , , judge investigator , place patient unacceptable risk he/she participate study . Examples medical condition , limited , follow : • Uncontrolled diabetes mellitus ( e.g. , glycosylated hemoglobin [ HbA1c ] &gt; 8 % ) , judge investigator 7 . Patients follow abnormal measurement screen perform within 2 week ( 14 day ) prior start study drug administration : Hemoglobin : &lt; 8 g/dL Neutrophil count : &lt; 1,200/µL Platelet count : &lt; 75,000/µL Serum aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) : &gt; 3 x upper limit normal ( ULN ) Bilirubin level : &gt; 1.5 x ULN Creatinine clearance : &lt; 50 mL/min via CockcroftGault formula ; proteinuria &gt; Grade 2 Plasma troponin I ( troponin T ) : &gt; ULN Prothrombin time activate partial thromboplastin time : &gt; 1.25 x ULN Potassium , correct calcium , magnesium level outside normal limit 8 . Any cardiac arrhythmia require antiarrhythmic medication 9 . Patients history seizures 10 . Patients know hypersensitivity histone deacetylase ( HDAC ) inhibitor component HBI8000 tablets 11 . Patients history complication malignant tumor , unless patient free disease 5 year longer , except follow , successfully treat , case exclude : Basal cell carcinoma skin Squamous cell carcinoma skin Cervical carcinoma situ Carcinoma situ breast An incidental histological finding prostate carcinoma ( TNM stage T1a T1b ) Earlystage gastric cancer treat endoscopic mucosal resection endoscopic submucosal dissection 12 . Patients uncontrolled intercurrent infection 13 . Patients active clinically significant bleed recently occur thrombotic disease , include patient high risk thromboembolic event willing take venous thromboembolic prophylaxis 14 . Women pregnant , woman willing stop breastfeeding study period 10 day last dose study drug , woman child bear potential , men sexual partner child bear potential willing use doublebarrier method study period least 3 month ( men ) least 1 month ( woman ) last dose study drug . Doublebarrier method define combination 2 effective contraceptive method , condom condom contain spermicide combination diaphragm , oral contraceptive , intrauterine device . Note : Female subject consider woman childbearing potential unless undergone permanent contraception postmenopausal . Postmenopausal define least 12 month without menses medical reason ( i.e. , chemical menopause treatment antimalignant tumor agent ) . 15 . Seropositivity human immunodeficiency virus ( HIV ) antibody 16 . Hepatitis B surface antigenpositive , hepatitis C virus antibody positive . In case hepatitis B core antibody and/or hepatitis B surface antibody positive even hepatitis B surface antigen negative , hepatitis B virus deoxyribonucleic acid ( DNA ) test [ realtime polymerase chain reaction ( PCR ] ) measurement ] perform positive , patient exclude 17 . Patients experimental clinical study investigational agent within 30 day start study drug administration ( 12 week investigational antibody therapy investigational ASCT ) , current clinical study investigational agent 18 . Patients history drug abuse longterm excessive alcohol consumption could affect study result assessment 19 . Patients consider investigator unsuitable study significant medical condition , laboratory abnormality , psychiatric illness would prevent patient participate study , condition confounds ability interpret data study</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>